Nephros is UNDERVALUED at 8.76 per share with modest projections ahead.
Nephros has Sharpe Ratio of -0.0757, which conveys that the firm had -0.0757% of return per unit of risk over the last 3 months. Macroaxis standpoint towards estimating the risk of any stock is to look at both systematic and unsystematic factors of the business, including all available market data and
technical indicators. Nephros exposes twenty-eight different
technical indicators, which can help you to evaluate volatility that cannot be
diversified away. Please be advised to verify Nephros
mean deviation of 1.94, and Risk Adjusted Performance of
(0.06) to check out the risk estimate we provide.
Typically, a company's
financial statements are the reports that show the
financial position of the company. There are three main documents that fall into the category of financial statements. These documents include Nephros income statement, its balance sheet, and the statement of cash flows. Potential Nephros investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Nephros investors may use each financial statement separately, they are all related. The changes in Nephros's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Nephros's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our
technical analysis and
fundamental analysis pages.
The goal of Nephros
fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of Nephros performance into the future periods or doing a reasonable stock valuation. The intrinsic value of Nephros shares is the value that is considered the true value of the share. If
the intrinsic value of Nephros is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares Nephros. Please read more on our
fundamental analysis page.
How effective is Nephros in utilizing its assets?
Nephros reports assets on its Balance Sheet. It represents the amount of Nephros resources that either has an existing economic value or will provide some form of benefits in the future. By effectively utilizing its assets, Nephros aims to generate revenue, control costs, drive operational efficiency, and enhance profitability. Optimizing asset utilization helps maximize shareholder value and maintain a competitive position in the Household Appliances space. To get a better handle on how balance sheet or income statements item affect Nephros volatility, please check the breakdown of all its
fundamentals.
Are Nephros Earnings Expected to grow?
The
future earnings power of Nephros involves the interaction of many company-specific, industry, and economic forces. Earnings estimates embody investors' opinions of Nephros factors such as sales growth, product demand, competitive industry environment, profit margins, and cost controls. Nephros
stock prices adjust as these expectations change or are proven wrong. The main thing to remember is that equities with high expected earnings growth tend to underperform the market because it is usually difficult to meet the market's high expectations. Companies with low earnings expectations tend to do better than expected. Please use our latest analysis of Nephros
expected earnings.
Nephros Gross Profit
Nephros Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Nephros previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Nephros Gross Profit growth over the last 10 years. Please check Nephros'
gross profit and other
fundamental indicators for more details.
Going after Nephros Financials
Although in the United States, the Securities and Exchange Commission has enforced strong rules to prevent insiders from engaging in insider trading, finding insiders among active shareholders of Nephros is not uncomon. There are few distinct groups of Nephros stakehholders that the SEC considers insiders. Investors usually gain information through their work as corporate directors, officers, or employees. If these individuals share the information with a friend, family, or business partner and the person who receives the information exchanges stock in the company, he or shie is also an insider. Let's take a look at how the ownership of Nephros is distributed among investors.
Ownership Allocation
The
market capitalization of Nephros is $68.04 Million. Over half of Nephros outstanding shares are owned by
institutional investors. These institutional investors are typically referred to corporate investors that shop for positions in a given instrument to benefit from reduced trade commissions. Consequently, these
institutions are subject to different rules and regulation than regular investors in Nephros. Please watch out for any change in the
institutional holdings of Nephros as this could mean something significant has changed or about to change at the company. Note, that even with negative
profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
| Retail Investors35.48% | Insiders12.3% | Institutions52.22% |
| Retail Investors | 35.48 |
| Insiders | 12.3 |
| Institutions | 52.22 |
Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Nephros has an asset utilization ratio of 331.23 percent. This implies that the company is making $3.31 for each dollar of assets. An increasing asset utilization means that Nephros is more efficient with each dollar of assets it utilizes for everyday operations.
| Current Assets | 16.35 Million | 77.29 |
| Assets Non Current | 2.81 Million | 13.27 |
| Goodwill | 2 Million | 9.43 |
Our perspective of the current Nephros rise
Current variance is at 7.1. Nephros exhibits very low volatility with skewness of 0.9 and kurtosis of 1.67. However, we advise investors to further study Nephros technical indicators to make sure all market info is available and is reliable. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Nephros' stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Nephros' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.
Nephros Implied Volatility
Nephros' implied volatility exposes the market's sentiment of Nephros stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Nephros' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Nephros stock will not fluctuate a lot when Nephros' options are near their expiration.
Our Takeaway on Nephros Investment
While some companies in the medical instruments & supplies industry are either recovering or due for a correction, Nephros may not be performing as strong as the other in terms of long-term growth potentials. While some stockholders may not share our view we believe that the current risk-reward utility is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Nephros.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Vlad Skutelnik is a Macroaxis Contributor. Vlad covers stocks, funds, cryptocurrencies, and ETFs that are traded in North America, focusing primarily on fundamentals, valuation and market volatility. He has many years of experience in fintech, predictive investment analytics, and risk management.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Nephros. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
[email protected]